Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset

Breast Cancer Research and Treatment

Volumn 162, Issue 1, 2017, Pages

  Harowicz, Michael R ^a   Robinson, Timothy J ^b,c   Dinan, Michaela A ^c   Saha, Ashirbani ^a   Marks, Jeffrey R ^c   Marcom, P Kelly ^c   Mazurowski, Maciej A ^a,d,e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Duke University   (United States)

^e DUKE UNIVERSITY   (United States)

Author keywords

Algorithm; Breast cancer; Histopathologic; Oncotype; Recurrence score

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ALGORITHM; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; FEMALE; GENE EXPRESSION ASSAY; GENETIC ANALYZER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOSIS RATE; PREDICTION; PREDICTIVE VALUE; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; TUMOR VOLUME; BREAST TUMOR; CANCER STAGING; DISEASE MANAGEMENT; GENE EXPRESSION PROFILING; GENETIC SCREENING; GENETICS; MIDDLE AGED; PROCEDURES; PROGNOSIS; RISK FACTOR; STANDARDS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE MANAGEMENT; FEMALE; GENE EXPRESSION PROFILING; GENETIC TESTING; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85008455041     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-4093-4     Document Type: Review

References (31)

1. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Eng J Med 351:2817–2826
2. (2006) NSABP study confirms Oncotype DX predicts chemotherapy benefit in breast cancer patients. Oncology 20:789–790
3. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734
4. Coates AS, Winer EP, Goldhirsch A et al (2015) Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26(8):1533–1546
5. Reed SD, Dinan MA, Schulman KA, Lyman GH (2013) Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med 15(3):203–211
6. Jacquemier J, Ginestier C, Rougemont J et al (2005) Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65:767–779
7. Abd El-Rehim DM, Ball G, Pinder SE et al (2005) High- throughput protein expression analysis using tissue microarray technology of a large well-characterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350
8. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374
9. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264–271
10. Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378
11. Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM (2012) Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 131:413–424
12. Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, Bhargava R (2013) Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol 26(5):658–664
13. Gage MM, Rosman M, Mylander WC et al (2015) A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay. Clin Breast Cancer 15(6):467–472
14. Tang P, Wang J, Hicks DG et al (2010) A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Investig 28(9):978–982
15. American Joint Committee on Cancer (2010) American Joint Committee on Cancer (AJCC) cancer staging manual, 7th edn. American Joint Committee on Cancer, Chicago
16. Flanagan MB, Dabbs DJ, Brufsky AM et al (2008) Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 21:1255–1261
17. Prat A, Cheang MC, Martin M et al (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31(2):203–209
18. Turner BM, Skinner KA, Tang P et al (2015) Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod Pathol 28(7):921–931
19. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795
20. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145
21. Pinder SE, Wencyk P, Sibbering DM et al (1995) Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71:146–149
22. Sparano JA (2006) TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347–350
23. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374
24. Blows FM, Driver KE, Schmidt MK et al (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7(5):e1000279
25. Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol 27:1168–1176
26. Cheang MCU, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750
27. Tang P, Wang J, Bourne P (2008) Molecular classifications of breast carcinomas with similar terminology and different definitions: are they the same? Hum Pathol 39:506–513
28. Offersen BV, Sørensen FB, Knoop A, Overgaard J (2003) Danish Breast Cancer Cooperative Tumour Biology Committee. Histopathology 43:573–582
29. Fasanella S, Leonardi E, Cantaloni C et al (2011) Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 6(Suppl 1):S7
30. Dabbs DJ, Klein ME, Mohsin SK et al (2011) High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 29:4279–4285
31. Ramsey SD, Barlow WE, Gonzalez-Angulo AM et al (2013) Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating Oncotype DX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials 34:1–9